Q3 FY26 · Ended Sep 26, 2026 · View SEC filing
A smaller segment earns nearly what the biggest does
Profit depends far more on Life Sciences Solutions than the revenue split suggests, because its sales carry much richer segment margins.
For investorsWhat the margin gain rests on once the one-offs fade
For foundersHow a standing cost system turns growth into margin
Costs grew more slowly than the 9.1% revenue gain, which the filing credits to productivity, including tariff refunds that need not repeat.
Open contracts worth $29.87B give visibility, though the longer-dated part sits in contract manufacturing and clinical research, the thinnest-margin work.
Instruments are 15.5% of revenue while consumables are 40.1%, a sign that each instrument placed keeps drawing supplies and service work.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Thermo Fisher Scientific from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
